Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

Yokohama City University Medical Center

Status: Unknown

Conditions: The Injection Burden

Treatments: Drug: IVA group

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02126904

1310006

Details and patient eligibility

About

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

Enrollment: 200 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept.

Exclusion criteria

• patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.

Trial design

200 participants in 1 patient group

IVR group

Treatment:

Drug: IVA group